<DOC>
	<DOCNO>NCT01457560</DOCNO>
	<brief_summary>This study assess immunogenicity safety GlaxoSmithKline ( GSK ) Biologicals ' ( formerly SmithKline Beecham Biologicals ' ) combine DTPa-HBV-IPV/Hib ( Infanrix hexa™ ) vaccine administer 3rd , 5th , 11th month life . The last dose DTPa-HBV-IPV/Hib give simultaneously one dose OPV vaccine .</brief_summary>
	<brief_title>Immunogenicity Reactogenicity DTPa-HBV-IPV/Hib Vaccine Followed Same Vaccine Oral Polio Vaccine</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Diphtheria</mesh_term>
	<mesh_term>Poliomyelitis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>The inclusion criterion check study entry . If criterion apply , subject eligible inclusion study . Healthy male female subject ≥12 &lt; 16 week life time first vaccination . Free obvious health problem establish medical history clinical examination enter study . Written inform consent obtain parents/guardians infant advise risk benefit study language clearly understood , performance study procedure . The exclusion criterion check study entry follow visit . If criteria applies study entry , subject eligible inclusion study . If criterion become applicable study , subject withdrawn . Use investigational nonregistered drug vaccine study vaccine ( ) within 30 day precede first dose study vaccine , plan use study period . Administration chronic immunosuppressant immunemodifying drug within three month vaccination ) . Administration vaccine foreseen study within 30 day dose study vaccine end 30 day . Previous vaccination diphtheria , tetanus , pertussis , hepatitis B , polio and/or Hib disease . History /or intercurrent diphtheria , tetanus , pertussis , hepatitis B , polio and/or Hib disease infection . Any confirm suspected immunosuppressive immunodeficient condition , include human immunodeficiency virus ( HIV ) infection . History allergic disease reaction likely exacerbate component vaccine . Major congenital defect serious chronic illness . History seizures neurological disease study entry . Administration immunoglobulins and/or blood product since birth , plan administration study period . Acute disease time enrolment .</criteria>
	<gender>All</gender>
	<minimum_age>12 Weeks</minimum_age>
	<maximum_age>16 Weeks</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Oral polio vaccine ( OPV )</keyword>
	<keyword>DTPa-HBV-IPV/Hib vaccine</keyword>
</DOC>